Treace Medical Q4 revenue beats estimates; sees likely revenue drop in 2026

Treace Medical Concepts

27/02/2026 12:13

Overview

Medical technology firm's Q4 revenue fell 9% yr/yr but beat analyst expectations

Company reported Q4 net loss of $9.4 mln, adjusted EBITDA decreased

Revenue decline due to shift towards lower-priced bunion kits

Outlook

Treace Medical expects 2026 revenue between $200 mln and $212 mln, flat to down 6% y/y

Company anticipates 2026 Adjusted EBITDA loss of $4 mln to $6 mln vs loss of $3.9 mln in 2025

Treace forecasts 50% reduction in cash usage for 2026

Result Drivers

PRODUCT MIX SHIFT - Revenue decline in Q4 2025 was primarily due to a shift towards lower-priced bunion kits

DEMAND FOR 3D SYSTEMS - Increased demand for 3D bunion correction systems drove case volume growth, per CEO John T. Treace

SURGEON BASE EXPANSION - Co increased net new active surgeons by 202, ending 2025 with 3,337 active surgeons

Company press release: ID:nGNX9FrHyR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$62.52 mln
$61.39 mln (6 Analysts)
Q4 EPS
-$0.15
Q4 Gross Margin
80.60%
Q4 Gross Profit
$50.40 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Treace Medical Concepts Inc is $3.00, about 42.9% above its February 26 closing price of $2.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)